JP2022507514A5 - - Google Patents

Info

Publication number
JP2022507514A5
JP2022507514A5 JP2021526509A JP2021526509A JP2022507514A5 JP 2022507514 A5 JP2022507514 A5 JP 2022507514A5 JP 2021526509 A JP2021526509 A JP 2021526509A JP 2021526509 A JP2021526509 A JP 2021526509A JP 2022507514 A5 JP2022507514 A5 JP 2022507514A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound according
cancer
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507514A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061750 external-priority patent/WO2020102686A1/en
Publication of JP2022507514A publication Critical patent/JP2022507514A/ja
Publication of JP2022507514A5 publication Critical patent/JP2022507514A5/ja
Pending legal-status Critical Current

Links

JP2021526509A 2018-11-16 2019-11-15 Erkインヒビター及びその使用 Pending JP2022507514A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862768565P 2018-11-16 2018-11-16
US62/768,565 2018-11-16
US201962908965P 2019-10-01 2019-10-01
US62/908,965 2019-10-01
PCT/US2019/061750 WO2020102686A1 (en) 2018-11-16 2019-11-15 Erk inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2022507514A JP2022507514A (ja) 2022-01-18
JP2022507514A5 true JP2022507514A5 (cg-RX-API-DMAC7.html) 2022-12-09

Family

ID=70730924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526509A Pending JP2022507514A (ja) 2018-11-16 2019-11-15 Erkインヒビター及びその使用

Country Status (12)

Country Link
US (1) US12428416B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880677A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022507514A (cg-RX-API-DMAC7.html)
KR (1) KR20210130701A (cg-RX-API-DMAC7.html)
CN (1) CN113423707A (cg-RX-API-DMAC7.html)
AU (1) AU2019381808A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009430A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119988A1 (cg-RX-API-DMAC7.html)
IL (1) IL283106A (cg-RX-API-DMAC7.html)
MX (1) MX2021005171A (cg-RX-API-DMAC7.html)
SG (1) SG11202104404XA (cg-RX-API-DMAC7.html)
WO (1) WO2020102686A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514448B2 (en) * 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
ZA200700751B (en) 2004-06-30 2008-08-27 Vertex Pharma Azalndoles useful as inhibitors of protein kinases
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
NZ590784A (en) * 2008-07-23 2012-12-21 Vertex Pharma Pyrazolopyridine kinase inhibitors
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
DE102009060174A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
US8697697B2 (en) 2011-01-04 2014-04-15 Kinentia Biosciences Llc Pyrazole derivatives as ERK inhibitors
US9096598B2 (en) 2011-10-03 2015-08-04 Merck Sharp & Dohme Corp. Azaindoles as Janus kinase inhibitors
EP2909206A1 (en) * 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
BR112015016580A2 (pt) 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
SI3052096T1 (en) * 2013-10-03 2018-04-30 Kura Oncology, Inc. EAQ inhibitors and application procedures
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
EP3170822A1 (en) * 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
CN107973783B (zh) * 2016-10-21 2024-09-06 正大天晴药业集团股份有限公司 作为erk抑制剂的苯胺嘧啶衍生物
CN108948002A (zh) 2017-05-19 2018-12-07 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用

Similar Documents

Publication Publication Date Title
RU2376287C2 (ru) Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac
JP2020503299A5 (cg-RX-API-DMAC7.html)
JP2009536620A5 (cg-RX-API-DMAC7.html)
RU2405780C2 (ru) Химические соединения
JP2022062168A5 (cg-RX-API-DMAC7.html)
RU2008122048A (ru) Аминопиримины в качестве ингибиторов киназ
CA2545427A1 (en) Selective kinase inhibitors
RU2017145026A (ru) Соединение, ингибирующее brk
JP2007517807A5 (cg-RX-API-DMAC7.html)
JP2017509586A5 (cg-RX-API-DMAC7.html)
RU2016110096A (ru) Новое хинолин-замещенное соединение
CY1118846T1 (el) Τριαζολοπυριδαζινες ως ρυθμιστες της κινασης τυροσινης
JP2016053042A5 (cg-RX-API-DMAC7.html)
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
JP2010509356A5 (cg-RX-API-DMAC7.html)
RU2009140407A (ru) СОЕДИНЕНИЯ ИМИДАЗ[1, 2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ
AR051342A1 (es) Derivados de purina, purinona, deazapurina y deazapurinona como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quina
PE20140411A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
RU2007148217A (ru) Получение производных n-фенил-2-пиримидинамина
PE20080067A1 (es) DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR)
SE0202133D0 (sv) Novel compounds
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
JP2009543771A5 (cg-RX-API-DMAC7.html)
MY121778A (en) Benzosulfone derivatives